RSV Immunoprophylaxis
Cross-source consensus on RSV Immunoprophylaxis from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Benefits
Comparisons
Evidence quality
Highlighted claims
- The protocol evaluates maternal RSV vaccination and infant monoclonal antibody prophylaxis for preventing medically attended RSV infection in infants aged 12 months or younger. — Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case–control study
- Nirsevimab and clesrovimab are single-dose extended half-life monoclonal antibodies with phase 3 efficacy greater than 75%. — Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case–control study
- Maternal RSV prefusion F vaccination protects infants through transplacental antibody transfer. — Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case–control study
- Postlicensure effectiveness may differ from clinical trial efficacy because of administration timing, host factors, pharmacokinetics, immune responses, healthcare access, and viral evolution. — Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case–control study
- The main exposure categories are maternal RSV vaccine and infant monoclonal antibody prophylaxis. — Real-world effectiveness of perinatal RSV immunoprophylaxis: protocol for a test-negative case–control study